This week, Andreessen Horowitz said it’s launching a fund dedicated to investments in bioinformatics and “beyond the pill” technology. The venture capital firm had already gotten its feet wet with investments in these areas, but a dedicated fund is something new and indicates an interest in ramping up its strategy. With its fund, the firm could make a big impact. Here are some insights on some challenges and opportunities in these areas and some companies the firm should consider.
